Anti-idiotypic antibody induction of anti-tumor response
US6042827A · kind A · utility
0Cited by
3References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 21, 1994 |
| Grant date | Mar 28, 2000 |
| Priority date | — |
| Expiry date | Jul 21, 2014 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/809
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Novel compositions and methods are described for stimulating a patient's immune system to tumor cells which bear a gp72 tumor-associated antigen and thereby eliciting a tumoricidal effect. Anti-idiotypic human monoclonal antibodies and idiotopic regions thereof to primary antibodies which bind selectively to an antigenic determinant of gp72 are provided to mediate the humoral and cellular components of the patient's immune system. The immunogenic agents find use both in vivo and in vitro.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.